• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Camden Property Trust Set to Join S&P 500; Matador Resources to Join S&P MidCap 400; Vir Biotechnology to Join S&P SmallCap 600

    3/29/22 6:43:00 PM ET
    $CPT
    $MTB
    $MTDR
    $PBCT
    Real Estate Investment Trusts
    Real Estate
    Major Banks
    Finance
    Get the next $CPT alert in real time by email

    NEW YORK, March 29, 2022 /PRNewswire/ -- S&P MidCap 400 constituent Camden Property Trust (NYSE:CPT) will replace People's United Financial Inc. (NASD: PBCT) in the S&P 500, S&P SmallCap 600 constituent Matador Resources Co. (NYSE:MTDR) will replace Camden Property Trust in the S&P MidCap 400 and Vir Biotechnology, Inc. (NASD: VIR) will replace Matador Resources in the S&P SmallCap 600 effective prior to the opening of trading on Monday, April 4.  S&P 500 constituent M&T Bank Corp. (NYSE:MTB) is acquiring People's United Financial in a deal expected to be completed on or about April 4. 

    Following is a summary of the changes that will take place prior to the open of trading on the effective date:

    Effective Date

    Index Name      

    Action

    Company Name

    Ticker

    GICS Sector

    April 4, 2022

    S&P 500

    Addition

    Camden Property Trust

    CPT

    Real Estate



    S&P 500

    Deletion

    People's United Financial

    PBCT

    Financials



    S&P MidCap 400

    Addition

    Matador Resources

    MTDR

    Energy



    S&P MidCap 400

    Deletion

    Camden Property Trust

    CPT

    Real Estate



    S&P SmallCap 600

    Addition

    Vir Biotechnology

    VIR

    Health Care



    S&P SmallCap 600

    Deletion

    Matador Resources

    MTDR

    Energy

    For more information about S&P Dow Jones Indices, please visit www.spdji.com

    ABOUT S&P DOW JONES INDICES

    S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.

    S&P Dow Jones Indices is a division of S&P Global (NYSE:SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spdji.com.

    FOR MORE INFORMATION:

    S&P Dow Jones Indices

    [email protected]

    Media Inquiries

    [email protected]

    Cision View original content:https://www.prnewswire.com/news-releases/camden-property-trust-set-to-join-sp-500-matador-resources-to-join-sp-midcap-400-vir-biotechnology-to-join-sp-smallcap-600-301513323.html

    SOURCE S&P Dow Jones Indices

    Get the next $CPT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CPT
    $MTB
    $MTDR
    $PBCT

    CompanyDatePrice TargetRatingAnalyst
    Vir Biotechnology Inc.
    $VIR
    2/24/2026$19.00Outperform → Strong Buy
    Raymond James
    S&P Global Inc.
    $SPGI
    2/17/2026$575.00Buy
    BofA Securities
    Matador Resources Company
    $MTDR
    1/27/2026$47.00Overweight → Equal Weight
    Wells Fargo
    M&T Bank Corporation
    $MTB
    1/7/2026Outperform → Peer Perform
    Wolfe Research
    M&T Bank Corporation
    $MTB
    1/7/2026$225.00Buy → Neutral
    BofA Securities
    M&T Bank Corporation
    $MTB
    12/12/2025$217.00Buy → Hold
    Truist
    Matador Resources Company
    $MTDR
    12/8/2025$53.00Buy
    Citigroup
    Camden Property Trust
    $CPT
    11/25/2025$118.00Overweight → Equal Weight
    Barclays
    More analyst ratings

    $CPT
    $MTB
    $MTDR
    $PBCT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Vir Biotechnology upgraded by Raymond James with a new price target

    Raymond James upgraded Vir Biotechnology from Outperform to Strong Buy and set a new price target of $19.00

    2/24/26 7:40:37 AM ET
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BofA Securities resumed coverage on S&P Global with a new price target

    BofA Securities resumed coverage of S&P Global with a rating of Buy and set a new price target of $575.00

    2/17/26 7:30:15 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    Matador Resources downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded Matador Resources from Overweight to Equal Weight and set a new price target of $47.00

    1/27/26 8:41:51 AM ET
    $MTDR
    Oil & Gas Production
    Energy

    $CPT
    $MTB
    $MTDR
    $PBCT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Biotech and Big Tech Drive the Morning Narrative

    DENVER, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Markets are opening with a cross-sector mix of breakthrough science, regulatory acceleration, and multi-gigawatt AI infrastructure commitments. From advanced materials to oncology platforms and hyperscale compute, today's developments are shaping a compelling growth narrative. KBLB) featured on Cover of March 2026 National Geographic" height="600" src="https://ml.globenewswire.com/Resource/Download/c66bcdc7-5761-4898-a027-43978e0ac618/kblb-national-geographic-march-2026-newsstand-cover-art.jpg" width="413" data-dpi="300" data-caption="Kraig Biocraft Laboratories (OTCQB:KBLB) featured on Cover of March 2026 National Geographic" data-filename="KBLB

    2/24/26 10:17:14 AM ET
    $LRMR
    $META
    $VIR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Computer Software: Programming Data Processing
    Technology

    S&P Cotality Case-Shiller Index Reports Annual Gain in December 2025

    The S&P Cotality Case-Shiller U.S. National Home Price NSA Index posted a 1.3% annual gain for December 2025, down from a 1.4% rise in the previous month.Inflation outpaced home price appreciation from June 2025 onward, eroding real home values through year-end and reversing a decade-long trend of positive real returns.Geographic divergence widened sharply: Chicago and New York led all markets with gains above 5%, while Tampa, Phoenix, Dallas, and Miami posted the steepest declines among markets that finished the year in negative territory.NEW YORK, Feb. 24, 2026 /PRNewswire/ -- S&P Dow Jones Indices (S&P DJI) today released the December 2025 results for the S&P Cotality Case-Shiller Indices

    2/24/26 10:00:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

    – Announces global strategic collaboration with Astellas to advance PSMA-targeted PRO-XTEN® dual-masked T-cell engager (TCE) VIR-5500 for the treatment of prostate cancer – Reports updated VIR-5500 Phase 1 dose-escalation data supporting a favorable safety profile and promising anti-tumor activity – Strong financial position with $781.6 million in cash and investments as of December 31, 2025 – Conference call scheduled for February 23, 2026, at 5:30 p.m. ET / 2:30 p.m. PT Vir Biotechnology, Inc. (NASDAQ:VIR), today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2025. "This is a seminal moment for Vir Biotechnology

    2/23/26 5:14:00 PM ET
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CPT
    $MTB
    $MTDR
    $PBCT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Joly Hubert bought $997,459 worth of shares (2,500 units at $398.98), increasing direct ownership by 1,515% to 2,665 units (SEC Form 4)

    4 - S&P Global Inc. (0000064040) (Issuer)

    2/12/26 4:01:28 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    President, S&P Global Mobility Eager William W bought $11,917 worth of shares (23 units at $517.58), increasing direct ownership by 0.26% to 8,724 units (SEC Form 4)

    4 - S&P Global Inc. (0000064040) (Issuer)

    1/15/26 4:01:18 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    EVP, Chief Financial Officer Macalik Robert T bought $57,375 worth of shares (1,500 units at $38.25) (SEC Form 4)

    4 - Matador Resources Co (0001520006) (Issuer)

    11/10/25 7:34:09 AM ET
    $MTDR
    Oil & Gas Production
    Energy

    $CPT
    $MTB
    $MTDR
    $PBCT
    SEC Filings

    View All

    SEC Form S-8 filed by Vir Biotechnology Inc.

    S-8 - Vir Biotechnology, Inc. (0001706431) (Filer)

    2/23/26 5:29:45 PM ET
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by Vir Biotechnology Inc.

    10-K - Vir Biotechnology, Inc. (0001706431) (Filer)

    2/23/26 5:27:59 PM ET
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vir Biotechnology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Unregistered Sales of Equity Securities, Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - Vir Biotechnology, Inc. (0001706431) (Filer)

    2/23/26 5:16:39 PM ET
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CPT
    $MTB
    $MTDR
    $PBCT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Accounting Officer Gallagher Michael P sold $18,325 worth of shares (169 units at $108.43), decreasing direct ownership by 0.42% to 39,640 units (SEC Form 4)

    4 - CAMDEN PROPERTY TRUST (0000906345) (Issuer)

    2/19/26 5:07:52 PM ET
    $CPT
    Real Estate Investment Trusts
    Real Estate

    EVP - Chief Operating Officer Baker Laurie sold $235,007 worth of shares (2,168 units at $108.40), decreasing direct ownership by 2% to 94,468 units (SEC Form 4)

    4 - CAMDEN PROPERTY TRUST (0000906345) (Issuer)

    2/19/26 5:04:39 PM ET
    $CPT
    Real Estate Investment Trusts
    Real Estate

    EVP-Production Stetson Glenn W covered exercise/tax liability with 2,362 shares, decreasing direct ownership by 2% to 94,470 units (SEC Form 4)

    4 - Matador Resources Co (0001520006) (Issuer)

    2/18/26 6:48:58 PM ET
    $MTDR
    Oil & Gas Production
    Energy

    $CPT
    $MTB
    $MTDR
    $PBCT
    Leadership Updates

    Live Leadership Updates

    View All

    S&P Global Appoints Chief Strategy Officer for Mobility Global Completing New Executive Leadership Team

    Martin Metzker to lead Strategy, Communications and Enterprise Marketing for Mobility Global in preparation for its planned separation into a standalone public companyNEW YORK, Feb. 19, 2026 /PRNewswire/ -- S&P Global (NYSE: SPGI) today announced the appointment of Martin Metzker as Chief Strategy Officer of S&P Global Mobility ("Mobility Global"), effective immediately. Mr. Metzker will be responsible for leading Mobility Global's Strategy function and overseeing Communications and Enterprise marketing for the business as it prepares for its planned separation from S&P Global into a standalone public company. Mr. Metzker joins the company from Boston Consulting Group, and will report to Bil

    2/19/26 4:15:00 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    RingCentral Set to Join S&P SmallCap 600

    NEW YORK, Feb. 9, 2026 /PRNewswire/ -- RingCentral Inc. (NYSE:RNG) will replace Hillenbrand Inc. (NYSE:HI) in the S&P SmallCap 600 effective prior to the opening of trading on Thursday, February 12. Lone Star Funds is acquiring Hillenbrand in a deal expected to be completed soon, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector Feb 12, 2026 S&P SmallCap 600 Addition RingCentral RNG Information Technology Feb 12, 2026 S&P SmallCap 600 Deletion Hillenbrand HI Industrials ABOUT S&P DOW JONES INDICES S&P Dow Jones Indices is the large

    2/9/26 6:08:00 PM ET
    $HI
    $RNG
    $SPGI
    Miscellaneous manufacturing industries
    Consumer Discretionary
    EDP Services
    Technology

    Merchants Bancorp Set to Join S&P SmallCap 600

    NEW YORK, Feb. 6, 2026 /PRNewswire/ -- Merchants Bancorp (NASD: MBIN) will replace TreeHouse Foods Inc. (NYSE:THS) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, February 11. Investindustrial S.A. and its affiliates are acquiring Treehouse Foods in a deal expected to be completed soon, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector Feb 11, 2026 S&P SmallCap 600 Addition Merchants Bancorp MBIN Financial Feb 11, 2026 S&P SmallCap 600 Deletion TreeHouse Foods THS Consumer Staples ABOUT S&P DOW

    2/6/26 6:24:00 PM ET
    $MBIN
    $SPGI
    $THS
    Major Banks
    Finance
    Finance: Consumer Services
    Packaged Foods

    $CPT
    $MTB
    $MTDR
    $PBCT
    Financials

    Live finance-specific insights

    View All

    Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

    – Announces global strategic collaboration with Astellas to advance PSMA-targeted PRO-XTEN® dual-masked T-cell engager (TCE) VIR-5500 for the treatment of prostate cancer – Reports updated VIR-5500 Phase 1 dose-escalation data supporting a favorable safety profile and promising anti-tumor activity – Strong financial position with $781.6 million in cash and investments as of December 31, 2025 – Conference call scheduled for February 23, 2026, at 5:30 p.m. ET / 2:30 p.m. PT Vir Biotechnology, Inc. (NASDAQ:VIR), today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2025. "This is a seminal moment for Vir Biotechnology

    2/23/26 5:14:00 PM ET
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer

    – Updated Phase 1 dose-escalation data (n=58) show VIR-5500 monotherapy has a favorable safety profile and was well tolerated with no dose-limiting toxicities observed to date – Dose-dependent anti-tumor activity was observed, with 82% PSA50 and 53% PSA90 declines and RECIST-evaluable objective responses (45% ORR in 5/11 patients) in ≥3,000 µg/kg Q3W dosing cohorts – Vir Biotechnology to host conference call today at 5:30 p.m. ET / 2:30 p.m. PT – Data will be presented at the 2026 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium on February 26 (Oral Abstract #17) Vir Biotechnology, Inc. (NASDAQ:VIR) today announced new data from the ongoing Phase 1 clinical tri

    2/23/26 5:02:00 PM ET
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer

    - Astellas and Vir Biotechnology to co-develop and co-commercialize VIR-5500 through a sharing of expenses and revenues -- Astellas to lead commercialization of VIR-5500 in the U.S. with Vir Biotechnology retaining option to co-promote, and Astellas will obtain exclusive rights to commercialize VIR-5500 ex-U.S. -- Vir Biotechnology will receive $335M in upfront and near-term milestone payments, will split U.S. profit/loss equally with Astellas (50/50), and is eligible to receive up to an additional $1.37B in development, regulatory and sales milestones, along with tiered, double-digit royalties on ex-U.S. net sales - - Vir Biotechnology to host conference call today at 2:30 p.m. PT / 5:30 p.

    2/23/26 5:00:00 PM ET
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CPT
    $MTB
    $MTDR
    $PBCT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by M&T Bank Corporation

    SC 13G - M&T BANK CORP (0000036270) (Subject)

    11/12/24 10:32:14 AM ET
    $MTB
    Major Banks
    Finance

    Amendment: SEC Form SC 13G/A filed by M&T Bank Corporation

    SC 13G/A - M&T BANK CORP (0000036270) (Subject)

    11/8/24 10:46:38 AM ET
    $MTB
    Major Banks
    Finance

    Amendment: SEC Form SC 13G/A filed by Matador Resources Company

    SC 13G/A - Matador Resources Co (0001520006) (Subject)

    11/7/24 10:52:17 AM ET
    $MTDR
    Oil & Gas Production
    Energy